At the virtual meeting between WHO / PAHO, the Cuban Medicines Regulatory Agency, directors of BioCubaFarma, the Center for Genetic Engineering and Biotechnology (CIGB) and the Finlay Vaccine Institute (IFV), which was hosted by the Genetic Engineering Center and Biotechnology (CIGB), the scientific results were presented in the clinical trials with the anticovid19 vaccines Abdala and Soberana.
Scientists from the Center for Genetic Engineering and Biotechnology (CIGB) showed data from clinical studies with Abdala, designed and developed by this center, and whose efficacy against symptomatic disease was 92.28%. For their part, scientists from the Finlay Vaccine Institute offered the results with Sovereign, designed and developed by that institution.
In this remote meeting with experts from both institutions, the Cuban regulatory authority, the Center for State Control of Medicines, Medical Equipment and Devices, CECMED, also participated. Its director, Dr. Olga Lidia Jacobo Casanueva, explained about the certification process of compliance with Good Clinical and Manufacturing Practices for both vaccines.
As expected, in the face of a process in which transparency has prevailed, the expert representatives of WHO / PAHO recognized the effort and results of Cuba in the development of vaccines against covid19 and the importance of having these vaccines for everyone who needs them.
comments on